SCHEMBL2030741

SCHEMBL2030741

CCOC(=O)c1ccc2c(c1)nc(N)n2C1CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ RPS6KB1 P23443 1/20 0.55
▸ ALDH1A1 P00352 5/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ MAPT P10636 3/20 0.49
▸ TP53 P04637 1/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ OPRM1 P35372 3/20 0.48
▸ OPRK1 P41145 3/20 0.48
▸ OGFRL1 Q5TC84 3/20 0.48
▸ OPRD1 P41143 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ GAA P10253 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ SIRT2 Q8IXJ6 4/20 0.47
▸ SIRT1 Q96EB6 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21310911 0.91 ALDH1A1 (0.52) L3MBTL1RPS6KB1ALDH1A1MAPK1MAPT
SCHEMBL2031012 0.90 RPS6KB1 (0.49) L3MBTL1RPS6KB1ALDH1A1MAPTTP53
SCHEMBL2031010 0.90 RPS6KB1 (0.49) L3MBTL1RPS6KB1ALDH1A1MAPTTP53
SCHEMBL22382488 0.89 RPS6KB1 (0.51) L3MBTL1RPS6KB1ALDH1A1MAPTTP53
SCHEMBL17582784 0.88 RPS6KB1 (0.48) L3MBTL1RPS6KB1ALDH1A1MAPK1MAPT
SCHEMBL5518664 0.85 RPS6KB1 (0.56) L3MBTL1RPS6KB1ALDH1A1MAPK1MAPT
SCHEMBL2032449 0.84 RPS6KB1 (0.47) L3MBTL1RPS6KB1ALDH1A1MAPTTP53
SCHEMBL2032453 0.84 RPS6KB1 (0.47) L3MBTL1RPS6KB1ALDH1A1MAPTTP53
SCHEMBL5514113 0.83 SIRT2 (0.54) L3MBTL1RPS6KB1ALDH1A1MAPK1MAPT
SCHEMBL21310910 0.81 GRK6 (0.46) RPS6KB1ALDH1A1MAPK1MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293923-B2 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase BIOGEN IDEC MA INC. (US) 2012-10-23 — — US disclosed
US-20110152260-A1 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase BIOGEN IDEC MA INC. (US) 2011-06-23 — — US disclosed
EP-2061786-A2 INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE Biogen Idec MA Inc. (US) 2009-05-27 — — EP disclosed
WO-2008030584-A2 INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN- 1 RECEPTOR-ASSOCIATED KINASE BIOGEN IDEC MA INC. (US) 2008-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152260-A1 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase IRAK1, IRAK2, IRAK3 L3MBTL1 3008/4885RPS6KB1 147/4885ALDH1A1 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback